# Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’

* INBS offers a patented, non-invasive testing solution positioned to disrupt a global drug screening market projected to reach $14.9 billion by 2030.
* The company is revenue-generating, with 148% year-over-year growth in FY 2024 and 450+ active customer accounts.
* Its Intelligent Fingerprinting system provides rapid, on-site results with a lower cost and higher convenience compared to traditional methods.
* The Intelligent Fingerprinting Drug Screening System is already in commercial use internationally, and a U.S. product launch is planned for 2025, with FDA 510(k) clearance in process and new patent protections underway.
* INBS is led by a seasoned executive team with global healthcare and commercialization experience.

 Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings such as opiates, cocaine, methamphetamine, and cannabis. This innovative approach positions INBS to transform drug testing protocols, particularly in industries where safety and speed are mission critical.

 The company’s vision is to redefine drug screening by removing the pain points of traditional testing methods, including biohazardous waste, privacy concerns, and long result turnaround times. With results in under 10 minutes and no need for gender-specific collectors or laboratory facilities, the system…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/intelligent-bio-solutions-inc-nasdaq-inbs-is-one-to-watch/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/inbs-disrupts-drug-screening-market-with-non-invasive-fingerprint-analysis/e51bca523dcd969c7a6e967f2068bd97) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1kgzhgk/inbs_disrupts_drug_screening_market_with/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/7/pintSlog.webp)